Sugi Predict

Sugi Predict / Compounds / SCHEMBL783254

SCHEMBL783254

SCHEMBL783254

C[Si](C)(C)c1cccc(Br)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ ACHE P22303 1/20 0.41
▸ NPC1 O15118 3/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MEN1 O00255 4/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ GAA P10253 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ RAPGEF4 Q8WZA2 1/20 0.38
▸ TAAR1 Q96RJ0 3/20 0.36
▸ C1S P09871 1/20 0.35
▸ PARP1 P09874 1/20 0.35
▸ GABRG2 P18507 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29945235 1.00 ALDH1A1 (0.48) ALDH1A1MAPK1ACHENPC1RAB9A
SCHEMBL10928549 0.98 ALDH1A1 (0.46) ALDH1A1MAPK1ACHENPC1RAB9A
SCHEMBL23457112 0.85 ALDH1A1 (0.48) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL4737005 0.82 GRM5 (0.49) ALDH1A1MAPK1ACHENPC1RAB9A
SCHEMBL4572715 0.81 ACHE (0.48) ACHEMAPT
SCHEMBL4876931 0.79 ALDH1A1 (0.46) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL4784480 0.79 ACHE (0.54) ALDH1A1ACHENPC1RAB9ASMN1; SMN2
SCHEMBL17937684 0.78 ALDH1A1 (0.41) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL28793384 0.78 ALDH1A1 (0.41) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL8723541 0.78 ALDH1A1 (0.41) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025127695-A1 ORGANIC ELECTROLUMINESCENT DEVICE 솔루스첨단소재 주식회사 2025-06-19 — — WO disclosed
CN-115362151-B Arylpiperidines as monoacylglycerol lipase modulators 詹森药业有限公司 2025-02-11 — — CN disclosed
EP-4448618-A1 METHOD FOR SEQUESTERING METHIONINE CONTAINED IN A LIQUID AND MATERIAL SUITABLE FOR IMPLEMENTING SUCH A METHOD Université de Bordeaux (FR) 2024-10-23 — — EP disclosed
US-20240092781-A1 ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-03-21 — — US disclosed
US-11787798-B2 Aryl piperidines as monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-17 — — US disclosed
WO-2023110915-A1 METHOD FOR SEQUESTERING METHIONINE CONTAINED IN A LIQUID AND MATERIAL SUITABLE FOR IMPLEMENTING SUCH A METHOD Universite de Bordeaux (FR) 2023-06-22 — — WO disclosed
EP-4126840-A1 ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS Janssen Pharmaceutica NV (BE) 2023-02-08 — — EP disclosed
CN-115362151-A Aryl piperidines as monoacylglycerol lipase modulators 詹森药业有限公司 2022-11-18 — — CN disclosed
US-20220363679-A1 ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-11-17 — — US disclosed
WO-2021191384-A1 ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-09-30 — — WO disclosed
WO-1997000877-A1 A PROCESS FOR PREPARING 1-(3-TRIALKYLSILYLPHENYL)-2,2,2-TRIFLUOROMETHYL ETHANONE DERIVATIVES HOECHST MARION ROUSSEL, INC. (US) 1997-01-09 — — WO disclosed
EP-0749972-A1 A process for preparing 1-(3-trialkylsilylphenyl)-2,2,2-trifluoromethyl ethanone derivatives MERRELL PHARMACEUTICALS INC. (US) 1996-12-27 — — EP disclosed
WO-1996014322-A1 PROCESS FOR THE PREPARATION OF 1-HALO-3-TRIALKYLSILANYL-BENZENE DERIVATIVES HOECHST MARION ROUSSEL, INC. (US) 1996-05-17 — — WO disclosed
US-5486638-A DEHALOGENATION AND FORMATION OF SILYL BOND ON BENZENE RING MARION MERRELL DOW INC. (US) 1996-01-23 — — US disclosed
EP-0409676-B1 Novel acetylcholinesterase inhibitors MERRELL DOW PHARMA (US) 1995-03-08 — — EP disclosed
CN-1027759-C Novel acetylcholinesterase inhibitors MERRELL DOW PHARMA (US) 1995-03-01 — — CN disclosed
CN-1076447-A Anti-tumor compositions and methods of treatment LILLY CO ELI (US) 1993-09-22 — — CN disclosed
EP-0409676-A1 Novel acetylcholinesterase inhibitors MERRELL DOW PHARMACEUTICALS INC. (US) 1991-01-23 — — EP disclosed
CN-1048389-A New acetylcholinesterase depressant MERRELL DOW PHARMA (US) 1991-01-09 — — CN disclosed
EP-0403713-A1 Novel acetylcholinesterase inhibitors MERRELL DOW PHARMACEUTICALS INC. (US) 1990-12-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092781-A1 ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP ALDH1A1 102/4885MAPK1 4113/4885ACHE 45/4885
US-11787798-B2 Aryl piperidines as monoacylglycerol lipase modulators MGLL, LPL, PNLIP ALDH1A1 102/4885MAPK1 4113/4885ACHE 45/4885
US-20220363679-A1 ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP ALDH1A1 102/4885MAPK1 4113/4885ACHE 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.